When specialist healthcare investment company Syncona Ltd discovered the ground-breaking cell therapy research being conducted by scientists at the University of Edinburgh it sparked a collaboration that went on to fuel the launch of pioneering biotechnology spinout Resolution Therapeutics.
Biotech spinout Resolution Therapeutics has announced it has raised £63.5 million in a series B financing round led by healthcare investor Syncona Ltd.
Biopharmaceutical spinout Resolution Therapeutics has announced the first patient has been dosed and safety cleared in the Phase I/II EMERALD study of its novel therapy for end-stage liver disease.
Four University of Edinburgh-supported companies have been named in Scotland’s Top 15 Tech Startups in recent analysis by data experts Beauhurst.
Taking an engineering approach to building biological systems – engineering biology – has spectacular potential to revolutionise how we diagnose and treat disease.
The Mass Spectrometry Core is a facility equipped with state-of-the-art instrumentation for sample preparation, chromatographic separation and mass spectrometry analysis for small molecule quantitation of biomarkers and drugs.
